



**DEPARTMENT OF HEALTH & HUMAN
SERVICES**

**Food and Drug Administration
Silver Spring, MD 20993**

NDA 21-567S-025

SUPPLEMENT APPROVAL

Bristol Myers Squibb Company
Attention: Hwei-Gene Wang, PhD
Associate Director, US Liaison
5 Research Parkway
Wallingford, CT 06492

Dear Dr. Wang:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 6, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Reyataz® atazanavir sulfate 100 mg, 150 mg, 200 mg and 300 mg capsules.

We acknowledge receipt of your amendments dated September 28, 2010, October 20, 2010, October 26, 2010, October 27, 2010, November 4, 2010, November 11, 2010, December 20, 2010, December 22, 2010, January 6, 2011, January 11, 2011, January 21, 2011, January 25, 2011, January 26, 2011, February 1, 2011 and February 3, 2011.

This Prior Approval supplemental new drug application was submitted to provide dosing recommendations for treatment of HIV-1 infection during pregnancy based on data from Study AI424-182, a study of atazanavir/ritonavir in combination with zidovudine/lamivudine in HIV-infected pregnant women.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert and text for the patient package insert) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements and any annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

NDA 21-567/S025

If you have any questions, please contact Venessa M Perry, MPH, Regulatory Project Manager, at 301.796.4891.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

VENESSA M PERRY
02/04/2011

JEFFREY S MURRAY
02/04/2011